Treatment of Patients With Major Depressive Disorder With MK0869 (0869-066)(COMPLETED)
Phase 3
Completed
- Conditions
- Major Depressive Disorder
- Registration Number
- NCT00034983
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Brief Summary
A clinical study to determine the efficacy and safety of an investigational medication (MK0869) in the treatment of depression
- Detailed Description
The duration of treatment is 1 year.
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 900
Inclusion Criteria
Not provided
Exclusion Criteria
Not provided
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Primary Outcome Measures
Name Time Method Long-term safety and tolerability. Duration of treatment
- Secondary Outcome Measures
Name Time Method Sexual dysfunction adverse experiences and gastrointestinal disturbance adverse experiences Duration of treatment